For teams who can't treat "we'll just use a public chatbot" as an acceptable answer.

Patent protection generally depends on an invention being new and undisclosed at filing. Sharing invention details with a third-party AI tool that isn't contractually bound to confidentiality can, in many jurisdictions, count as public disclosure, and in some countries there's no grace period at all. A single paste can permanently forfeit patent rights before a filing is ever made.

Lawyers have a professional duty to protect client confidentiality, and the special legal protection that normally covers attorney-client communication may not automatically extend to conversations held with a public AI tool whose provider isn't bound to keep them confidential. Ethics bodies have begun formally requiring lawyers to assess this risk before using generative AI on client matters.

Drug formulas, assay results, and clinical data are trade secrets and pre-publication IP. Industry research has found that only a small fraction of life-science organizations have automated controls to stop sensitive data leaking into AI tools, while the large majority already have some sensitive data exposed to AI systems in one form or another.

Healthcare privacy regulation generally requires a formal data-handling agreement with any vendor that touches patient data, and most consumer-tier AI tools don't offer one. Regulators have issued substantial fines tied to improper data-handling agreements, and real-world cases have linked AI-adjacent tooling to large-scale patient data exposure.

Certain technical data tied to defense and dual-use technology is treated as a controlled export. Sending it to servers accessible from outside the country, or to infrastructure that doesn't meet specific government security standards, can itself be a violation, independent of intent. Contract requirements are extending to any subcontractor, regardless of size.